Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is currently conducting a Phase 3 study titled Phase 3, ...

Amgen Inc. (NASDAQ:AMGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Amgen Inc. (NASDAQ:AMGN) reported ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a ...

Amgen is also a component of the Dow Jones Industrial Average and Nasdaq-100 index, making its shares highly liquid. Lastly, the biotech's annualized yield now sits at an all-time high.

Dec 12 (Reuters) - Amgen Inc (AMGN.O) on Monday agreed to buy Horizon Therapeutics Plc (HZNP.O) in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in ...

Since then, Amgen's stock has been on a fairly steady incline, and on Monday, it closed at a price of $294.43. At that point, those 173 shares would have been worth approximately $50,936.

Amgen’s shares fell 21 cents to $89.29 in trading Tuesday. The company’s case adds to a string of major settlements the federal government has secured from pharmaceutical giants.